Echo Therapeutics to Present at Prestigious Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference
FRANKLIN, Mass., Sept. 16 /PRNewswire/ -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE ), a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced that Patrick Mooney, M.D., Echo's Chairman and Chief Executive Officer, will present at the prestigious Accredited Members, Inc. (AMI) Fall 2010 Small Cap/Micro Cap Investment Conference. The conference is scheduled for September 20-22 at the Loew's Coronado Bay Resort and Spa in San Diego, CA. Echo's presentation is scheduled for 1:50 p.m. PT on September 21, 2010.
Dr. Mooney will discuss the Company's development progress. Echo Therapeutics recently announced the successful completion of a clinical study to evaluate the ability of Prelude to ablate the skin prior to the application of OTC 4% lidocaine cream for faster-acting local dermal anesthesia. In addition, Echo recently completed the initial product development work on its Prelude SkinPrep System and the Company is now focused on completing the final steps of its regulatory advance to commercialization and leveraging its key strategic partnerships to generate product-related revenue.
The Accredited Members, Inc. Fall 2010 Small Cap/Micro Cap Investment Conference is expected to feature 19 private and public presenting companies. Presentations will be made to more than 400 expected attendees, each a verified accredited investor. In addition, Echo Therapeutics will be featured on the AMI website at http://www.accreditedmembers.com , for one year.
About Echo TherapeuticsEcho is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital